Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities.

Combined EGFR and mTOR knockdown also tended to reduce the size of resultant TAD mutant tumors, but this effect was more variable, and hence, did not reach statistical significance compared to control (Fig. 6L ).

also in 111,027 other papers